FDA Form 483
- Why Work With NSF?
An FDA Form 483 is issued to firm management at the conclusion of an inspection when an investigator has observed any conditions that may constitute violations of the Food, Drug and Cosmetic (FD&C) Act and applicable regulations and requirements. It is important that companies take 483 observations seriously and respond to them in an appropriate and timely manner.
Responses to 483s need to be carefully crafted to reflect a firm’s understanding and commitment to remedy the objectionable observations in a holistic manner that focuses on the entire system rather than on the specific observation. The 483 is not inclusive of all objectionable conditions, but reflects only what was noted during that particular inspection. Companies are therefore encouraged to take the opportunity to assess their quality system as a whole and address any gaps present beyond those noted on the 483.
NSF Pharma Biotech experts have been part of the regulatory authority and industry for decades. They can offer unique insights into the 483 observations and help your company draft communication to the FDA and take the necessary corrective actions to remediate objectionable conditions.
For more information about NSF Pharma Biotech regulatory enforcement action support in the U.S., email firstname.lastname@example.org or call +1 202.822.1850.
For more information about NSF Pharma Biotech regulatory enforcement action support in Europe, email email@example.com or call +44 1751 432 999.
Why Work With NSF?
Our team includes former U.S. FDA inspectors and experts with decades of experience helping companies develop strategic plans to address and to respond to FDA 483s. Our experts have a proven track record for addressing the most complex regulatory problems and compliance issues.
- 1 day ago
FDA Regulatory and Compliance News FDA announced the approval of Covidien’s VenaSeal closure system, the first to permanently treat varicose...
- 1 week ago
FDA Regulatory and Compliance News FDA announced the approval of Eisai Inc.’s Lenvima (lenvatinib) to treat patients with progressive, differentiated...
NSF International cordially invites you to join us at the 54th Annual Meeting and ToxExpo When: March 22 – 26,...
- Monday, March 2, 2015
- 1:00pm - 2:00pm GMT
- Webinar, United Kingdom
- Tuesday, March 3, 2015
- 8:30am - 3:00pm GMT
- Amsterdam, Netherlands
- Monday, March 9, 2015
- 8:30am - 3:00pm GMT
- York, United Kingdom
- Monday, March 23, 2015
- 8:30am - 1:00pm GMT
- Manchester, United Kingdom